338 related articles for article (PubMed ID: 24073621)
1. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
[No Abstract] [Full Text] [Related]
2. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2016; 32(6):341-2. PubMed ID: 27333156
[No Abstract] [Full Text] [Related]
3. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2013; 29(6):513-4. PubMed ID: 23841863
[No Abstract] [Full Text] [Related]
4. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2014 Oct; 30(8):603-4. PubMed ID: 25280174
[No Abstract] [Full Text] [Related]
5. Notification vs approval.
Novack GD
Ocul Surf; 2007 Jul; 5(3):255-8. PubMed ID: 17660899
[No Abstract] [Full Text] [Related]
6. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
7. Fix the antibiotics pipeline.
Cooper MA; Shlaes D
Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
[No Abstract] [Full Text] [Related]
8. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
9. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
10. Pharma's year of trouble and strife.
Frantz S
Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
[No Abstract] [Full Text] [Related]
11. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
12. The year's new drugs & biologics 2016: Part II - Trends and highlights of an unforgettable year.
Graul AI; Dulsat C; Tracy M; Cruces E
Drugs Today (Barc); 2017 Feb; 53(2):117-158. PubMed ID: 28387389
[TBL] [Abstract][Full Text] [Related]
13. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2017 Jun; 33(5):335-336. PubMed ID: 28441083
[No Abstract] [Full Text] [Related]
14. Novelty in the target landscape of the pharmaceutical industry.
Agarwal P; Sanseau P; Cardon LR
Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
[No Abstract] [Full Text] [Related]
15. The balancing act.
Nat Rev Drug Discov; 2003 Sep; 2(9):683. PubMed ID: 12953693
[No Abstract] [Full Text] [Related]
16. The identity problem.
Nat Biotechnol; 2010 Sep; 28(9):877. PubMed ID: 20829806
[No Abstract] [Full Text] [Related]
17. The FDA Breakthrough-Drug Designation - Four Years of Experience.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
[No Abstract] [Full Text] [Related]
18. A new era in drug regulation?
Dresser R
Hastings Cent Rep; 2005; 35(3):10-1. PubMed ID: 16092391
[No Abstract] [Full Text] [Related]
19. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
20. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
